AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30984999 — intervention group
Group type: COMPARATOR
Intervention: Conventional LOR - Perifix®
Number of subjects: 170
Study 31119905 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day course of complex decongestive physiotherapy (CDP)
Number of subjects: 26
Study 31119905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of complex decongestive physiotherapy (CDP)
Number of subjects: 26
Study 31119905 — intervention group
Group type: COMPARATOR
Intervention: Multilayered compression
Number of subjects: 26
Study 26495784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase (72,000 lipase units/meal, 36,000/snack)
Number of subjects: 54
Study 26495784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 24468407 — intervention group
Group type: EXPERIMENTAL
Intervention: Prismatic adaptation (PA) with a leftward aftereffect administered outside the scanner.
Number of subjects: 17
Study 24468407 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional activation in the left anterior insula and left superior frontal gyrus immediately after PA compared to before PA during the time reproduction task.
Number of subjects: 17
Study 24468407 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional activation in the left middle frontal gyrus after 30 minutes compared to before PA.
Number of subjects: 17
Study 21911045 — intervention group
Group type: EXPERIMENTAL
Intervention: Fufangkushen colon-coated capsule (FCC)
Number of subjects: 320
Study 21911045 — intervention group
Group type: COMPARATOR
Intervention: Huidi (HD, mesalazine enteric-coated tablets)
Number of subjects: 320
Study 19819724 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 800 mg oral daily for 20 weeks
Number of subjects: 9
Study 19819724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 18067816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin infusion (6000 U/kg for 30 min, then 1000 U.kg(‐1).h(‐1) until end of operation)
Number of subjects: 24
Study 18067816 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (same volume as ulinastatin)
Number of subjects: 24
Study 16289802 — intervention group
Group type: COMPARATOR
Intervention: Hypnotic suggestions inducing negative emotions
Number of subjects: 0
Study 16289802 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of pain-related anger and sadness
Number of subjects: 0
Study 16289802 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions to increase desire for relief
Number of subjects: 0
Study 16289802 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions to decrease desire for relief
Number of subjects: 0
Study 16289802 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-induced changes in pain
Number of subjects: 0
Study 16289802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-evoked cardiac responses (R-R interval decrease)
Number of subjects: 0
Study 16289802 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation and multiple regression analyses
Number of subjects: 0
Study 12930252 — intervention group
Group type: EXPERIMENTAL
Intervention: Earliest atrial activation during tachycardia (ES group, n = 9)
Number of subjects: 16
Study 12930252 — intervention group
Group type: COMPARATOR
Intervention: Slow potential during sinus rhythm (SP group, n = 7)
Number of subjects: 16
Study 12930252 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional slow potential-guided RFCA in ES group
Number of subjects: 16
Study 12930252 — intervention group
Group type: EXPERIMENTAL
Intervention: Abl/His-CS ratio
Number of subjects: 16
Study 12930252 — intervention group
Group type: EXPERIMENTAL
Intervention: A/V ratio
Number of subjects: 16
Study 10973133 — intervention group
Group type: EXPERIMENTAL
Intervention: S. melongena infusion (N = 19)
Number of subjects: 38
Study 10973133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 19)
Number of subjects: 38
Study 10973133 — intervention group
Group type: EXPERIMENTAL
Intervention: S. melongena infusion with dietary orientation (N = 16)
Number of subjects: 38
Study 10973133 — intervention group
Group type: EXPERIMENTAL
Intervention: S. melongena infusion without dietary orientation (N = 38)
Number of subjects: 38
Study 8826621 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing information-literacy program
Number of subjects: 0
Study 8826621 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional evaluation process
Number of subjects: 0
Study 1400877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone enanthate (TE; 100 mg weekly) for 3 months
Number of subjects: 13
Study 1400877 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 3 months
Number of subjects: 13
Study 3930121 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 92
Study 3930121 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and plaster cast
Number of subjects: 92
Study 3305794 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched allogenic bone marrow transplantation (BMT) following preparation with cyclophosphamide and fractionated total body irradiation (TBI)
Number of subjects: 40
Study 3305794 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of acute graft-v-host disease (GVHD)
Number of subjects: 40
Study 3305794 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy with oral methotrexate and mercaptopurine
Number of subjects: 40
Study 31286929 — intervention group
Group type: EXPERIMENTAL
Intervention: RLPD group
Number of subjects: 47
Study 31286929 — intervention group
Group type: COMPARATOR
Intervention: ACL group
Number of subjects: 47
Study 28173782 — intervention group
Group type: EXPERIMENTAL
Intervention: HealtheSteps™ program
Number of subjects: 110
Study 28173782 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 110
Study 25441591 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown flaxseed (BF)
Number of subjects: 75
Study 25441591 — intervention group
Group type: EXPERIMENTAL
Intervention: Golden flaxseed (GF)
Number of subjects: 75
Study 25441591 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - Wheat bran
Number of subjects: 75
Study 25441591 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (BF, GF, CG)
Number of subjects: 75
Study 24118114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1711
Study 24118114 — intervention group
Group type: COMPARATOR
Intervention: UFH + Abciximab
Number of subjects: 1711
Study 21458651 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-assisted mandibular dentures
Number of subjects: 0
Study 21458651 — intervention group
Group type: COMPARATOR
Intervention: Conventional mandibular dentures
Number of subjects: 0
Study 21458651 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachycephalic group
Number of subjects: 0
Study 21458651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolichocephalic group
Number of subjects: 0
Study 18662491 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB-based intervention with persuasive messages designed to change beliefs
Number of subjects: 300
Study 18662491 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 300
Study 16430721 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 74
Study 16430721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 15333404 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 10 mg/mL
Number of subjects: 150
Study 15333404 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1 mg/mL
Number of subjects: 150
Study 15333404 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.5 mg/mL
Number of subjects: 150
Study 11187176 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 0
Study 11187176 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy regular training
Number of subjects: 0
Study 9352760 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens Servo 900C ventilator at CPAP level of 0.5 kPa
Number of subjects: 13
Study 9352760 — intervention group
Group type: COMPARATOR
Intervention: Continuous flow CPAP (CF-CPAP) at CPAP level of 0.5 kPa
Number of subjects: 13
Study 9352760 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens Servo 900C ventilator
Number of subjects: 13
Study 8470632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg four times daily
Number of subjects: 328
Study 8470632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg four times daily
Number of subjects: 328
Study 8470632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 3780291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium bromide 100 mg twice daily for 3 days before and 100 mg 1 hour before examination
Number of subjects: 18
Study 3780291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3780291 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 18
Study 29975092 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive training in two versions of an avoidance learning task
Number of subjects: 0
Study 29975092 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive training in an appetitive slips-of-action task
Number of subjects: 0
Study 29975092 — intervention group
Group type: EXPERIMENTAL
Intervention: Two independent attempts to replicate the original demonstration
Number of subjects: 0
Study 27721231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold dialysis solution at 35.5°C
Number of subjects: 46
Study 27721231 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysis solution at 37°C
Number of subjects: 46
Study 25153486 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS) alone
Number of subjects: 193
Study 25153486 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on therapies (cytotoxic agents, biotherapies, intravenous immunoglobulins, and plasma exchanges)
Number of subjects: 193
Study 22695364 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 10-20 mg·kg·d orally
Number of subjects: 151
Study 20512350 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete PANP + LLND surgery combined with intraoperative radiotherapy (preserved group)
Number of subjects: 55
Study 20512350 — intervention group
Group type: COMPARATOR
Intervention: Pelvic autonomic nerve resection + LLND surgery (resected group)
Number of subjects: 55
Study 18719669 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training for 12 weeks
Number of subjects: 41
Study 15972865 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus cisplatin
Number of subjects: 482
Study 15972865 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 482
Study 10522354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 32
Study 10522354 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 32
Study 10522354 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 32
Study 8747374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 8747374 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroxyphenylretinamide
Number of subjects: 0
Study 8747374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and 4-hydroxyphenylretinamide
Number of subjects: 0
Study 2196926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone cream
Number of subjects: 0
Study 2196926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1% hydrocortisone cream and 2% miconazole cream
Number of subjects: 0
Study 2196926 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone alone
Number of subjects: 0
Study 6101961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol 10 mg four times daily
Number of subjects: 0
Study 6101961 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 4 mg four times daily
Number of subjects: 0
Study 6101961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study 30010773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 273
Study 30010773 — intervention group
Group type: COMPARATOR
Intervention: Td
Number of subjects: 273
Study 26940987 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia (33.0°C)
Number of subjects: 87
Study 26940987 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36.8°C)
Number of subjects: 87
Study 24567515 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI categories in DLBCL patients
Number of subjects: 1549
Study 24567515 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI categories in HL patients
Number of subjects: 1549
Study 24567515 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI categories in FL patients
Number of subjects: 1549
Study 24567515 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP treatment in males with DLBCL
Number of subjects: 1549
Study 22700717 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe (S + E)
Number of subjects: 39
Study 22700717 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (S)
Number of subjects: 39
Study 22700717 — intervention group
Group type: COMPARATOR
Intervention: Lipid-lowering treatment (LLT)
Number of subjects: 39
Study 19962941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.125 to 0.75 mg/day for 6 weeks)
Number of subjects: 0
Study 19962941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0
Study 19962941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17377856 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct autologous retransfusion of shed thoracic blood (350 ml)
Number of subjects: 44
Study 17377856 — intervention group
Group type: COMPARATOR
Intervention: Control group (350 ml saline)
Number of subjects: 44
Study 17377856 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct autologous retransfusion of shed thoracic blood
Number of subjects: 44
Study 16352934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX)
Number of subjects: 25
Study 16352934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of ramosetron (RAM) combined with 12 mg of dexamethasone (DEX)
Number of subjects: 25
Study 12171817 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation at 2 L/min
Number of subjects: 75
Study 9832489 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma BNP levels in ARVD patients
Number of subjects: 149
Study 9832489 — intervention group
Group type: COMPARATOR
Intervention: Plasma BNP levels in RVOT patients
Number of subjects: 149
Study 9832489 — intervention group
Group type: COMPARATOR
Intervention: Plasma BNP levels in control subjects
Number of subjects: 149
Study 8088143 — intervention group
Group type: EXPERIMENTAL
Intervention: Softened fabrics
Number of subjects: 15
Study 8088143 — intervention group
Group type: COMPARATOR
Intervention: Unsoftened fabrics
Number of subjects: 15
Study 2732867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based ORS
Number of subjects: 93
Study 2732867 — intervention group
Group type: COMPARATOR
Intervention: Glucose ORS
Number of subjects: 93
Study 30099811 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 5% ointment
Number of subjects: 30
Study 30099811 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 30
Study 27661023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordimax (abluminal biodegradable polymer SES)
Number of subjects: 402
Study 27661023 — intervention group
Group type: COMPARATOR
Intervention: Cypher Select (durable polymer SES)
Number of subjects: 402
Study 24411819 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐Centered Advance Care Planning for Teens With Cancer (FACE‐TC)
Number of subjects: 30
Study 24411819 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 22128789 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel with MTC‐2G
Number of subjects: 41
Study 22128789 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel alone
Number of subjects: 41
Study 22128789 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 41
Study 21293742 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of vitamin C daily
Number of subjects: 384
Study 21293742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin C supplementation)
Number of subjects: 384
Study 18547452 — intervention group
Group type: EXPERIMENTAL
Intervention: MCHW intervention
Number of subjects: 5240
Study 16036167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger capsule
Number of subjects: 80
Study 16036167 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 80
Study 16036167 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle filled with ginger capsules
Number of subjects: 80
Study 16036167 — intervention group
Group type: COMPARATOR
Intervention: Bottle filled with placebo capsules
Number of subjects: 80
Study 12203743 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal relationship with the specialist (trust, care, understanding, respect, time given, being listened to, openness and honesty)
Number of subjects: 20
Study 12203743 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of recurrence, life expectancy, side-effects, quality of life
Number of subjects: 20
Study 12203743 — intervention group
Group type: EXPERIMENTAL
Intervention: Further treatment to reduce risk
Number of subjects: 20
Study 12203743 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor variations in treatment protocol
Number of subjects: 20
Study 9066931 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Winter-Tozer equation
Number of subjects: 104
Study 9066931 — intervention group
Group type: COMPARATOR
Intervention: Winter-Tozer equation (original)
Number of subjects: 104
Study 1785672 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP + Bleo
Number of subjects: 84
Study 1785672 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐COPP
Number of subjects: 84
Study 6803278 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (5 g)
Number of subjects: 0
Study 6803278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (125 mg three times daily with meals) and L-tryptophan (3 g at 10 PM)
Number of subjects: 0
Study 6803278 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (100 mg at 10 PM)
Number of subjects: 0
Study 6803278 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 569
Study 30735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 569
Study 30735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 569
Study 30735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic switch during the 8-week acute phase
Number of subjects: 569
Study 30735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher positive symptoms at the endpoint
Number of subjects: 569
Study 30735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 569
Study 30735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CGI-S score at the endpoint
Number of subjects: 569
Study 29066452 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 15828
Study 26498430 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous whole-body vibrations (WBV) at 40 Hz, 4 mm for 60s and 90s
Number of subjects: 36
Study 26498430 — intervention group
Group type: COMPARATOR
Intervention: Control group performing similar exercises without vibrations
Number of subjects: 36
Study 25058216 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (500 IU/kg per dose)
Number of subjects: 200
Study 25058216 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 200
Study 25058216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin transfusion threshold of 7 g/dL
Number of subjects: 200
Study 25058216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin transfusion threshold of 10 g/dL
Number of subjects: 200
Study 25058216 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion threshold of 10 g/dL
Number of subjects: 200
Study 22733316 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 441
Study 22733316 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 441
Study 19777213 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg BZP
Number of subjects: 27
Study 19777213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17580150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus conversion treatment (RAPA)
Number of subjects: 110
Study 17580150 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) reduction
Number of subjects: 110
Study 15446319 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 105
Study 15446319 — intervention group
Group type: COMPARATOR
Intervention: ATG
Number of subjects: 105
Study 11475846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound skin measurement
Number of subjects: 103
Study 10817004 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (at a dilution of 1 mg/ml)
Number of subjects: 88
Study 10817004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (at a dilution of 10 mg/ml)
Number of subjects: 88
Study 10817004 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 88
Study 10817004 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 88
Study 10817004 — intervention group
Group type: COMPARATOR
Intervention: Both Morphine and Tramadol
Number of subjects: 88
Study 7602396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 33
Study 7602396 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented fixation
Number of subjects: 33
Study 7602396 — intervention group
Group type: COMPARATOR
Intervention: Cemented and uncemented fixation
Number of subjects: 33